Stay updated with breaking news from Nasdaq Tvtx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has received an average rating of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective […]
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective among […]
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024...
Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities researchers at HC Wainwright cut their FY2028 earnings estimates for Travere Therapeutics in a report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will earn $4.29 per share for the year, down from their previous estimate of $4.66. HC […]
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price target lifted by HC Wainwright from $17.00 to $19.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 248.62% from the company’s […]